ARQT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Arcutis Biotherapeutics Inc (ARQT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong revenue growth, positive analyst sentiment, and promising product performance. Despite insider selling, the overall outlook is favorable for long-term gains.
The stock exhibits bullish technical indicators. The MACD is positive and expanding, the RSI is neutral at 68.881, and the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels, with the next resistance at 29.256.
Strong Q4 financial performance with an 81.6% YoY revenue increase.
Positive clinical trial results for ZORYVE foam, with 77% of users achieving clear skin in 8 weeks.
Recognition from the National Psoriasis Foundation and a 'Best of Beauty Breakthrough Award' for ZORYVE.
Increased analyst price targets and confidence in the company's market potential.
Insider selling has increased significantly by 512.52% in the last month.
Net income dropped to 0 in Q4, indicating profitability challenges.
In Q4 2025, revenue increased by 81.48% YoY to $129.5M, gross margin improved to 90.97%, and EPS rose by 44.44% YoY to -0.13. However, net income fell to 0, reflecting ongoing profitability issues.
Analysts are bullish on ARQT. H.C. Wainwright raised the price target to $34 from $30, and Mizuho raised it to $37 from $32, citing strong prescription trends and confidence in ZORYVE's market potential.
